Selection for neutralization resistance of the simian/human immunodeficiency virus SHIV(SF33A) variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation

Cecilia Cheng-Mayer, Amanda Brown, Janet Harouse, Paul A Luciw, Allen J. Mayer

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

We previously reported on the in vivo adaptation of an infectious molecular simian/human immunodeficiency virus (SHIV) clone, SHIV(SF33), into a pathogenic biologic viral variant, designated SHIV(SF33A). In the present study, we show that SHIV(SF)33(A) is resistant to neutralization by human immunodeficiency virus (HIV) and SHIV antisera. Multiple amino acid substitutions accumulated over time throughout the env gene of SHIV(SF)33(A); some of them coincided with the acquisition of the neutralization resistance of the virus. Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. To determine whether potential glycosylation changes within these principal neutralization domains of HIV type 1 formed the basis for the resistance to serum neutralization of SHIV(SF33A), mutant viruses were generated on the backbone of parental SHIV(SF33) and tested for their neutralization sensitivity. The mutations generated did not alter the in vitro replication kinetics or cytopathicity of the mutant viruses in T-cell lines. However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIV(SF33). The combination of the V1 and V3 mutations conferred an additive effect on neutralization resistance over that of the single mutations. Taken together, these data suggest that (i) SHIV variants with changes in the Env SU can be selected in vivo primarily by virtue of their ability to escape neutralizing antibody recognition and (ii) carbohydrates play an important role in conferring neutralization escape, possibly by altering the structure of envelope gp120 or by shielding principal neutralization sites.

Original languageEnglish (US)
Pages (from-to)5294-5300
Number of pages7
JournalJournal of Virology
Volume73
Issue number7
StatePublished - 1999

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
glycosylation
Glycosylation
neutralization
glycoproteins
Glycoproteins
HIV
Viruses
viruses
blood serum
mutation
Mutation
env Genes
mutants
amino acid substitution
Amino Acid Substitution
Human immunodeficiency virus 1
Neutralizing Antibodies
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

@article{2f51be0e0c4c4fe2a729a8d0a550c7f0,
title = "Selection for neutralization resistance of the simian/human immunodeficiency virus SHIV(SF33A) variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation",
abstract = "We previously reported on the in vivo adaptation of an infectious molecular simian/human immunodeficiency virus (SHIV) clone, SHIV(SF33), into a pathogenic biologic viral variant, designated SHIV(SF33A). In the present study, we show that SHIV(SF)33(A) is resistant to neutralization by human immunodeficiency virus (HIV) and SHIV antisera. Multiple amino acid substitutions accumulated over time throughout the env gene of SHIV(SF)33(A); some of them coincided with the acquisition of the neutralization resistance of the virus. Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. To determine whether potential glycosylation changes within these principal neutralization domains of HIV type 1 formed the basis for the resistance to serum neutralization of SHIV(SF33A), mutant viruses were generated on the backbone of parental SHIV(SF33) and tested for their neutralization sensitivity. The mutations generated did not alter the in vitro replication kinetics or cytopathicity of the mutant viruses in T-cell lines. However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIV(SF33). The combination of the V1 and V3 mutations conferred an additive effect on neutralization resistance over that of the single mutations. Taken together, these data suggest that (i) SHIV variants with changes in the Env SU can be selected in vivo primarily by virtue of their ability to escape neutralizing antibody recognition and (ii) carbohydrates play an important role in conferring neutralization escape, possibly by altering the structure of envelope gp120 or by shielding principal neutralization sites.",
author = "Cecilia Cheng-Mayer and Amanda Brown and Janet Harouse and Luciw, {Paul A} and Mayer, {Allen J.}",
year = "1999",
language = "English (US)",
volume = "73",
pages = "5294--5300",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Selection for neutralization resistance of the simian/human immunodeficiency virus SHIV(SF33A) variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation

AU - Cheng-Mayer, Cecilia

AU - Brown, Amanda

AU - Harouse, Janet

AU - Luciw, Paul A

AU - Mayer, Allen J.

PY - 1999

Y1 - 1999

N2 - We previously reported on the in vivo adaptation of an infectious molecular simian/human immunodeficiency virus (SHIV) clone, SHIV(SF33), into a pathogenic biologic viral variant, designated SHIV(SF33A). In the present study, we show that SHIV(SF)33(A) is resistant to neutralization by human immunodeficiency virus (HIV) and SHIV antisera. Multiple amino acid substitutions accumulated over time throughout the env gene of SHIV(SF)33(A); some of them coincided with the acquisition of the neutralization resistance of the virus. Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. To determine whether potential glycosylation changes within these principal neutralization domains of HIV type 1 formed the basis for the resistance to serum neutralization of SHIV(SF33A), mutant viruses were generated on the backbone of parental SHIV(SF33) and tested for their neutralization sensitivity. The mutations generated did not alter the in vitro replication kinetics or cytopathicity of the mutant viruses in T-cell lines. However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIV(SF33). The combination of the V1 and V3 mutations conferred an additive effect on neutralization resistance over that of the single mutations. Taken together, these data suggest that (i) SHIV variants with changes in the Env SU can be selected in vivo primarily by virtue of their ability to escape neutralizing antibody recognition and (ii) carbohydrates play an important role in conferring neutralization escape, possibly by altering the structure of envelope gp120 or by shielding principal neutralization sites.

AB - We previously reported on the in vivo adaptation of an infectious molecular simian/human immunodeficiency virus (SHIV) clone, SHIV(SF33), into a pathogenic biologic viral variant, designated SHIV(SF33A). In the present study, we show that SHIV(SF)33(A) is resistant to neutralization by human immunodeficiency virus (HIV) and SHIV antisera. Multiple amino acid substitutions accumulated over time throughout the env gene of SHIV(SF)33(A); some of them coincided with the acquisition of the neutralization resistance of the virus. Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120. To determine whether potential glycosylation changes within these principal neutralization domains of HIV type 1 formed the basis for the resistance to serum neutralization of SHIV(SF33A), mutant viruses were generated on the backbone of parental SHIV(SF33) and tested for their neutralization sensitivity. The mutations generated did not alter the in vitro replication kinetics or cytopathicity of the mutant viruses in T-cell lines. However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIV(SF33). The combination of the V1 and V3 mutations conferred an additive effect on neutralization resistance over that of the single mutations. Taken together, these data suggest that (i) SHIV variants with changes in the Env SU can be selected in vivo primarily by virtue of their ability to escape neutralizing antibody recognition and (ii) carbohydrates play an important role in conferring neutralization escape, possibly by altering the structure of envelope gp120 or by shielding principal neutralization sites.

UR - http://www.scopus.com/inward/record.url?scp=0033033625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033033625&partnerID=8YFLogxK

M3 - Article

C2 - 10364275

AN - SCOPUS:0033033625

VL - 73

SP - 5294

EP - 5300

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 7

ER -